SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Effective, February 1,2023, the Texas Health and Human Services Commission (HHSC) will update the prior authorization criteria for Amvuttra (procedure code J0225).
Amvuttra (vutrisiran) is a transthyretin-directed small interfering RNA indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated (HATTR) amyloidosis in adults.
How this impacts providers: Members must meet the following criteria for approval for 12 months:
Initial Requests
Member is 18 years of age or older
Diagnosis of hereditary transthyretin (hATTR) amyloidosis (diagnosis code: 5.1), supported by
Transthyretin (TTR) mutation proven by genetic testing
Clinical signs and symptoms of the disease (e.g., peripheral/autonomic neuropathy, motor disability)
Member will not receive Amvuttra (vutrisiran) therapy in combination with other polyneuropathy hATTR amyloidosis therapies (e.g., inotersen, tafamidis meglumine or patisiran).
Member will receive vitamin A supplementation at the recommended daily allowance while on Amvuttra (vutrisiran) therapy.
Member has not had a liver transplant.
Renewal or Continuation Therapy
Member has previously received treatment with Amvuttra (vutrisiran) without an adverse reaction.
Member has a positive clinical response to Amvuttra (e.g., improved neurologic impairment, improved motor function, slowing of disease progression).
Next steps for providers: Providers should share this communication with their staff. Refer to the Outpatient Drug Services Handbook Chapter of the Texas Medicaid Provider Procedure Manual (TMPPM) for more details on the clinical policy and prior authorization requirements.
